AA 863

Also Known As:

AA-863

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Glioma (Gliomas) 06/01/1990 - "The results of the monolayer studies showed potent and dose dependent inhibitory effects on the proliferation of glioma cells (IC50/one week treatment/of AA-863: 9.0 microM, IC50 of U-60,257: 40.0 microM). " 06/01/1990 - "The effects of two specific 5-lipoxygenase inhibitors AA-863 and U-60,257 (piriprost) on the growth of two human glioma cell lines, U-343 MGa and U-251 MG were investigated. " 06/01/1990 - "Effects of the 5-lipoxygenase inhibitors AA-863 and U-60,257 on human glioma cell lines."
2.	Neoplasms (Cancer) 06/01/1990 - "The experiments made on the tumor spheroids suggested an inhibitory effect on proliferation and volume growth already at lower doses (AA-863: 0.4-2.0 microM, U-60,257: 1.0-5.0 microM), a dose range where effects were not found in monolayers. "
3.	Necrosis 06/01/1990 - "At higher doses (AA-863: 10.0-30.0 microM, U-60,257: 30.0-90.0 microM) the experiments with spheroids failed to demonstrate a further inhibitory effect on spheroid volume, probably attributed to phenomena such as swelling of cells, dissociation of spheroid structure and development of necrosis. "